Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide and GnRH Agonist in AR-Expressing Salivary Gland Carcinoma
NCT04325828Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2020
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in salivary gland carcinoma (SGC), sponsored by Janssen Pharmaceutical. Started Apr 2020; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT04325828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325828.